We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Multiple-Ascending Dose (Japan) (MAD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00538174
First Posted: October 2, 2007
Last Update Posted: March 23, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin in diabetic Japanese subjects administered for 14 days

Condition Intervention Phase
Diabetes Mellitus, Type 2 Drug: Dapagliflozin Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • AEs, vital signs & physical exam [ Time Frame: scr, Days -3, -1, 1, 2, 7, 12, 13, 14, 15, 21 ]
  • ECGs [ Time Frame: scr, Days -1, 1, 2, 7, 12, 13, 14, 15, 21 ]
  • Clinical labs [ Time Frame: scr, Days -1, 2, 7, 12, 14, 15, 21 ]
  • Urine safety markers [ Time Frame: Days -1, 1, 14 ]

Secondary Outcome Measures:
  • 24 hr PK blood & urine samples [ Time Frame: Days 1 & 14 ]
  • Serum glucose, serum insulin, serum c-peptide [ Time Frame: Days -1, 1, 14 ]
  • Serum fructosamine [ Time Frame: Days -1, 14, 4 h ]
  • OGTT [ Time Frame: Days -2, 13 (after 10 h fast) ]
  • 24h urine [ Time Frame: Days -1, 1 & 14 for glucose, creatinine & calcium ]

Enrollment: 36
Study Start Date: November 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
2.5 mg
Drug: Dapagliflozin
Tablets, Oral, once daily up, to 14 days
Experimental: Arm 2
10 mg
Drug: Dapagliflozin
Tablets, Oral, once daily up, to 14 days
Experimental: Arm 3
20 mg
Drug: Dapagliflozin
Tablets, Oral, once daily up, to 14 days
Placebo Comparator: Arm 4 Drug: placebo
Tablets, Oral, 0 mg, once daily, up to 14 days

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Japanese male and female subjects
  • Ages 20 to 70 years old
  • Established diagnosis of T2DM
  • BMI < 32 kg/m2
  • Fasting glucose ≤ 240 mg/dL, while on antidiabetic diet alone
  • HbA1C 6.0 - 10.0%

Exclusion Criteria:

  • Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment
  • History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome
  • History of incontinence or bladder dysfunction including nocturia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00538174


Locations
Japan
Local Institution
Suita, Osaka, Japan, 5650853
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers K.K.
  More Information

Additional Information:
Publications:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00538174     History of Changes
Other Study ID Numbers: MB102-025
First Submitted: October 1, 2007
First Posted: October 2, 2007
Last Update Posted: March 23, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases